

Global Pneumonia Vaccine Market Outlook 2020

https://marketpublishers.com/r/GE7DF7A76BFEN.html

Date: May 2015

Pages: 50

Price: US\$ 1,500.00 (Single User License)

ID: GE7DF7A76BFEN

Abstracts

According to a new research, introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children, a classic example of herd immunity. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected.

According to our report, "Global Pneumonia Vaccine Market Outlook 2020", the Pneumonia vaccine market for 2014, which has been estimated at US\$ 5.9 Billion, is expected to reach US\$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The current market and future forecasts for the industry have been derived. The regional distribution of the current market has also been discussed. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government's focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.

As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.

Lastly, the report discusses the three major players in the industry viz., GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlighting the current share of every player in the market. This is followed by company profiles, wherein the general business along with key financials of every



player has been provided. At the end of every profile, a strength and weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.



Contents

- 1. ANALYST VIEW
- 2. RESEARCH METHODOLOGY
- 3. PNEUMOCOCCAL DISEASE AND VACCINE
- 4. GLOBAL PNEUMONIA VACCINE MARKET OUTLOOK 2020
- 4.1 Key Geographical Markets
- 5. REGULATORY OVERVIEW
- 5.1 United States
- 5.2 Europe
- 5.3 Rest of the World
 - 5.3.1 India
 - 5.3.2 China
 - 5.3.3 Japan

6. COMPETITIVE ASSESSMENT

- 6.1 Market Share of Major Players
- 6.2 Company Profiles
 - 6.2.1 GlaxoSmithKline
 - 6.2.1.1 Business Overview
 - 6.2.1.2 Key Financials
 - 6.2.1.3 Strengths and Weaknesses
 - 6.2.2 Pfizer
 - 6.2.2.1 Business Overview
 - 6.2.2.2 Key Financials
 - 6.2.2.3 Strengths and Weaknesses
 - 6.2.3 Merck
 - 6.2.3.1 Business Overview
 - 6.2.3.2 Key Financials
 - 6.2.3.3 Strengths and Weaknesses



List Of Figures

LIST OF FIGURES:

Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia

Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in 5 Years of Age

Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US

Figure 4-4: Pneumonia Vaccine Market (Million US\$), 2009-2014

Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014

Figure 4-6: Pneumonia Vaccine Market (Million US\$), 2014-2020

Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014

Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a

Pneumococcal Vaccination: United States, 1997-2013

Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013

Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014

Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014

Figure 6-3: GSK - Revenue by Geographic Segment (%), 2014

Figure 6-4: GSK - Revenue by Business Segment (%), 2014

Figure 6-5: GSK - Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014

Figure 6-6: GSK - Synflorix Sales (Million GBP), 2010-2014

Figure 6-7: Pfizer - Revenue by Geography (%), 2014

Figure 6-8: Pfizer - Revenue by Business Segment (%), 2014

Figure 6-9: Pfizer - Prevnar Family Sales (Million USD), 2010-2014

Figure 6-10: Merck - Revenue by Business Segment (%), 2014

Figure 6-11: Merck - Revenue by Geography (%), 2014

Figure 6-12: Merck - Pneumovax 23 Sales (Million USD), 2010-2014



List Of Tables

LIST OF TABLES:

Table 4-1: Current levels of coverage for interventions that prevent (vaccination)

Pneumonia

Table 6-1: GSK - Pneumonia Vaccine Portfolio

Table 6-2: GSK - Key Financials (Million GBP), 2012-2014

Table 6-3: GSK - Strengths and Weaknesses

Table 6-4: Pfizer - Pneumonia Vaccine Portfolio

Table 6-5: Pfizer - Key Financials (Million US\$), 2012-2014

Table 6-6: Pfizer - Strengths and Weaknesses

Table 6-7: Merck - Pneumonia Vaccine Portfolio

Table 6-8: Merck - Key Financials (Millions US\$), 2012-2014

Table 6-9: Merck - Strengths and Weaknesses



I would like to order

Product name: Global Pneumonia Vaccine Market Outlook 2020

Product link: https://marketpublishers.com/r/GE7DF7A76BFEN.html

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE7DF7A76BFEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970